Skip to content
Buy This GLP
← Research
Evidence

Does Insurance Cover GLP-1 Weight Loss Drugs? What Decides Your Bill

Coverage depends on the drug, indication and plan. The Medicare GLP-1 Bridge adds a separate route for eligible patients; Medicaid and employer benefits vary.

Editorial profile: Carla MedinaBuy This GLP Editorial Team7 min read

Use the insurance coverage worksheet to check the drug list and approval rules for your prescription. Keep the plan’s written criteria handy if your clinician needs to submit a request.

It depends on your plan, drug and indication. The separate Medicare GLP-1 Bridge offers eligible beneficiaries a $50 copay, outside ordinary Part D coverage. State Medicaid and employer benefits differ. A diabetes prescription can follow different rules from one for weight management.[6]

What do Wegovy and Zepbound cost with insurance?

Ask your insurer or pharmacy for the amount you would pay for your exact drug, form, dose, and supply. Check the plan’s drug list first, then ask about prior authorization, the remaining deductible, and whether you owe a flat copay or a percentage of the price. If approval is pending, ask what the same prescription would cost after approval.

Check manufacturer savings eligibility separately. Lilly’s Zepbound savings terms distinguish the single-dose pen from the KwikPen and limit savings by offer. Novo Nordisk’s Wegovy savings page lists its own eligibility and terms. Ask the pharmacy to quote the amount after any discount you qualify for.

Use the GLP-1 price check to compare a cash quote for the same medication and supply. Include any required care fee, and ask your insurer whether a cash purchase would count toward your deductible.

In KFF’s 2026 employer survey, 18% of firms with at least 200 workers that offered health benefits said their largest plan covered a GLP-1 drug for weight loss, compared with 19% in 2025 [7]. The employer coverage guide explains how to check the rules for your plan. If you have Medicare, the Medicare coverage guide explains how the reason for the prescription affects coverage. Of the Americans who tried to get one, about half did not.

The exclusion is written into the statute

Medicare Part D was built with weight-loss drugs explicitly excluded. The statutory exclusion applies when a drug is used for weight loss alone. A prescription for a separately covered indication can follow different rules.[1] The Medicare GLP-1 Bridge is now a separate demonstration route. CMS lists July 1, 2026, through December 31, 2027, with a $50 copay for eligible beneficiaries. Its payments do not count toward Part D true out-of-pocket spending.[6]

State Medicaid programs are not bound by that exclusion. They have moved in different directions. That is why coverage for one drug differs across a state line. A study of state Medicaid coverage and reimbursement examined those policies and their trends from 2011 to 2022[2]. Commercial coverage is its own patchwork. A policy review calls access severely limited despite what the newer agents do. It draws the parallel with bariatric surgery, where coverage widened eventually[3].

What a copay does to whether anyone finishes

The clearest published link between price and behavior is one cohort. It followed 15,811 commercially insured US adults who started semaglutide for weight management, from June 2021 to December 2023[4]. By the fifth month, 46% had stopped. Among those who started after the shortage resolved, the rate was 48%[4].

Stopping tracked what the patient paid. It ran 41% in the lowest copayment quintile, $1 to $54 a month. It ran 51% in the highest, $161 to $1,460 a month[4]. Lower income and lower education tracked the same way[4].

Coverage changes what gets prescribed, not just what gets paid

One study brackets a policy change directly. A tertiary center reviewed 2,060 patients seen in January and April 2024, either side of a state Medicaid coverage change[5]. Privately insured patients were likelier to be prescribed semaglutide or tirzepatide. The adjusted odds ratio was 2.744 (p < 0.001)[5].

In the January window, Black patients were 49% less likely to be prescribed those drugs (p = 0.003). Hispanic patients were 47% less likely (p = 0.025). In April, after the MassHealth coverage change, the study did not detect those same differences[5]. This before-and-after comparison at one center cannot establish how much of the change was due to the policy.

What this means for a cash price

The guide to advertised and billed prices explains how separate membership fees change a cash quote. Use the four-week billing guide to put both quotes on the same time basis if the cash program charges every 28 days. Ask for the full charge up front if the advertised rate requires prepayment.

The Calibrate review shows how a coaching and care fee can sit outside the prescription benefit. Check the program charge, lab costs and medication copay separately when you budget.

Care and medication may also be separate transactions. Call-On-Doc’s review distinguishes a delivery-inclusive program from pharmacy pickup, where a $60 monthly subscription or $75 one-time visit leaves the medication charge to the pharmacy. The FOLX Health review shows how a membership, visits, labs, and pharmacy charges can affect the total separately. Ask which charges your plan covers before comparing an insured prescription with a cash quote.

The discontinuation study followed commercially insured patients. Its copayment groups cannot tell you what happens when someone switches to a cash-pay program. If you are weighing a prepaid treatment plan, ask what you would owe if your clinician recommends stopping early.

Frequently asked

Does Medicare cover a GLP-1 for weight loss?
Ordinary Part D excludes drugs used only for weight loss. The separate Medicare GLP-1 Bridge began in July 2026 and gives eligible beneficiaries access to selected drugs with a $50 copay outside Part D.
How much does a copay change the odds of staying on treatment?
In a cohort of 15,811 commercially insured adults, five-month discontinuation ran 41% in the lowest copay quintile and 51% in the highest. That is an association in claims data, not a randomized comparison.
Is a cash price better or worse than an insured one?
Compare your plan’s out-of-pocket amount with an itemized cash quote for the same drug and dose. The studies cited here do not establish whether the payment route affects weight outcomes.

Sources

  1. [1] Hernandez I, et al. (2024). Medicare Part D Coverage of Anti-obesity Medications: a Call for Forward-Looking Policy Reform Journal of General Internal Medicine. PMID 37715099
  2. [2] Liu BY, et al. (2024). State Coverage and Reimbursement of Antiobesity Medications in Medicaid JAMA. PMID 38483403
  3. [3] Gasoyan H, et al. (2022). Addressing insurance-related barriers to novel antiobesity medications: Lessons to be learned from bariatric surgery Obesity (Silver Spring). PMID 36190393
  4. [4] Xu Y, et al. (2025). Titration and discontinuation of semaglutide for weight management in commercially insured US adults Obesity (Silver Spring). PMID 40464214
  5. [5] Wasden K, et al. (2026). Disparities in Prescription of Long-Acting GLP-1s Obesity (Silver Spring). PMID 41771653
  6. [6] Centers for Medicare & Medicaid Services (2026). Medicare GLP-1 Bridge CMS. Source
  7. [7] KFF (2026). 2026 Employer Health Benefits Survey KFF. Source

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence